|
Clarient Reports 2009 Fourth Quarter; Year-End Results (PR Newswire)
Clarient, Inc. , a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the fourth quarter and year ended December 31, 2009.  Fourth quarter 2009 net revenue was $23.3 million, compared to $21.9 million for the same period in 2008.
us.rd.yahoo.com 2010-03-13
FDA Panel Backs Device For Epilepsy
An FDA panel narrowly backed the use of Medtronic's "deep-brain stimulation" device in certain epilepsy patients.
online.wsj.com 2010-03-13
Is the Tide Turning Back in Takeda’s Favor?
EP Vantage submits: With so many high-profile pipeline setbacks over the past couple of years, could the tide be turning back in Takeda’s (TKPHF.PK) favor with regard to one of its biggest and most valuable products?Wednesday’s patent litigation settlement with Watson Pharmaceuticals (WPI) will delay the launch of Watson’s generic version of key diabetes drug Actos until August 2012, a full 19 months after expiry of the drug’s main patent in January 2011, the point at which the market is currently expecting significant generic competition. If Takeda can similarly ward off other generic threats the gains could be significant, adding $1.9bn to profits from Actos (see tables below). Takeda’s shares gained 1% in trading Thursday to reach a 12-month high of ¥4,075.Complete Story »
seekingalpha.com 2010-03-12
InterMune: Pulmonary Fibrosis Drug Could Open Doors, Expand the Product Pipeline
Prohost Biotech submits:The FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbiet (pirfenidone), developed by the biotech firm InterMne (ITMN), for idiopathic pulmonary fibrosis (IPF). The same drug is approved in Japan for IPF and sold under the trade name Pirespa by Shionogi (SGIOF.PK) in that country. Both Intermune and Shionogi had licensed pirfenidone from Marnac and its co-licensor, KDL GmbH. Intermune got the rights to sell the compound in the United States, Europe and other territories except in Japan, Taiwan and South Korea, while Shionogi & Co. Ltd. got the rights for Japan. Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. Complete Story »
seekingalpha.com 2010-03-12
Peregrine Pharmaceuticals, Inc. F3Q10 (Qtr End 01/31/10) Earnings Call Transcript
Peregrine Pharmaceuticals, Inc. (PPHM)F3Q10 (Qtr End 01/31/10) Earnings CallMarch 11, 2010 11:30 am ETComplete Story »
seekingalpha.com 2010-03-12
XOMA Ltd. Q4 2009 Earnings Call Transcript
XOMA Ltd. (XOMA)Q4 2009 Earnings CallMarch 11, 2010 4:30 pm ETComplete Story »
seekingalpha.com 2010-03-12
Three Biotech ETFs for Different Risk Appetites
Tom Lydon (ETF Trends) submits: The biotechnology sector has been hopping around like Tigger lately; mergers and acquisitions dot the space, some stocks are rocketing higher while others are taking a few lumps. This is why biotech ETFs might be a better way to access the sector than picking stocks.The biotech industry at large may appeal to some of the more conservative investors out there, says Don Dion for The Street. Many of the larger ETFs are taking unique, well-balanced approaches to the industry, but which you go for depends on what your goals are.Complete Story »
seekingalpha.com 2010-03-12
Female Condom Launches in DC - Video
The MAC AIDS Fund, the DC Department of Health, the Female Health Company, Washington AIDS Partnership, and CVS/pharmacy Launch Innovative Partnership to Provide Access to Female Condoms in Washington, D.C.
feedproxy.google.com 2010-03-12
Awash in Fake Drugs, Nigerians Fight Back
A new technology is helping companies and consumers detect fake pharmaceuticals in Nigeria.
online.wsj.com 2010-03-12
Cell Therapeutics: The Jury's Still Out on Pixatrone
David Greene submits:With the announcement after yesterday's market close that Abbott Laboratories (NYSE:ABT) is buying Facet Biotech Corp. (NASDAQ:FACT) for approximately $450 million in cash or $27/share - a nice 67% premium to yesterday's closing market price - the focus will be on other potential targets for acquisition. Abbott said the Facet Biotech acquisition expands the company's access in immunology and oncology. The compounds include daclizumab that is expected to move into Phase III development in the second quarter 2010 to treat multiple sclerosis (MS).But there are more companies with promising drugs under development which could attract generous valuations by other Big Pharma's. Cell Therapeutics (NASDAQ:CTIC) recently announced that the Food and Drug Administration (FDA) approved a third-party manufacturing site for the production of the company's experimental cancer drug. CTIC's drug, Pixantrone, is being reviewed by the FDA as a potential therapeutic for aggressive non-Hodgkin's lymphoma that has not responded to other approved therapies or if the lymphoma returned after initially appearing to be responding to other therapies. The FDA had expressed concerns on the efficacy and safety of Pixatrone in early February, prompting a sharp selloff in CTIC stock which is just recently rebounding from.Complete Story »
seekingalpha.com 2010-03-11
Biotechnology M&As, Wholesale Mix the Markets and ETFs
Tom Lydon (ETF Trends) submits: Mergers and acquisitions are starting to be a sign of the times. An unexpected decline in wholesale inventories wasn’t enough to put the markets in the red in early trading, thanks to a slew of M&A deals in the biotechnology and financial sectors. Abbott Laboratories (ABT) is going to buy Facet Biotech Corp. (FACT) for $450 million. Abbott’s bid bested a failed bid from Biogen Idec Inc. (BIIB). The move would add immunology and oncology to Abbott’s repertoire. These deals signal more than just the health of aspects of the biotech sector; it’s a sign of renewed confidence in the economic recovery. It wouldn’t be surprising to see more deals in this and other sectors take place in the coming months. iShares Nasdaq Biotechnology (IBB) is up about 1% this morning.Complete Story »
seekingalpha.com 2010-03-11
QLT Inc. Q4 2009 Earnings Call Transcript
QLT Inc. (QLTI)Q4 2009 Earnings CallMarch 10, 2010 8:30 am ETComplete Story »
seekingalpha.com 2010-03-11
ETF Spotlight: First Trust NYSE Arca Biotechnology
Tom Lydon (ETF Trends) submits: ETF Spotlight on First Trust NYSE Arca Biotechnology (FBT), part of a weekly series. Complete Story »
seekingalpha.com 2010-03-11
Biotech IPO: AVEO Pharma Develops Cancer Therapeutics
SA Editor Mohit Manghnani submits:AVEO Pharmaceuticals (AVEO), a biopharmaceutical company developing cancer therapeutics, is expected to price its IPO this week. Business Overview (from prospectus)Complete Story »
seekingalpha.com 2010-03-11
InterMune's Surprising Rise
Derek Lowe submits: If you want to know why people continue to speculate in biotech stocks, just take a look at the stairsteppy last few days of trading in InterMune (ITMN). Last Thursday it was at $15; now it's at $38. And all you have to do to cash in on these moves is read the FDA's mind!That's not a money-making proposition, in case anyone thinks I'm advocating it. There are just too many surprises. But Intermune's good fortune started last week, when the FDA briefing documents came out on the application for the company's pirfenidone for idiopathic pulmonary fibrosis and were characterized as "not as bad as they could have been". (The company's history of overzealous PR wasn't helping it at this point.) And if you still don't think that the moves in the stock have been surprising, consider that two ITMN executives sold shares after the first jump, missing out on the second one completely when the FDA advisory panel gave the drug a favorable recommendation.Complete Story »
seekingalpha.com 2010-03-11
We Keep Moving Team Introduction - Video
“WE KEEP MOVING” TELLS THE STORIES OF PEOPLE LIVING WITH MS THROUGH A TEN-WEEK, CROSS-COUNTRY JOURNEY
feedproxy.google.com 2010-03-11
Clarient Reports 2009 Fourth Quarter; Year-End Results (PR Newswire)
Clarient, Inc. , a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the fourth quarter and year ended December 31, 2009. Â Fourth quarter 2009 net revenue was $23.3 million, compared to $21.9 million for the same period in 2008.
us.rd.yahoo.com 2010-03-11
Clarient 4th-quarter loss widens on higher costs (AP)
Diagnostic and laboratory services company Clarient Inc. said Wednesday its fourth-quarter loss widened slightly on higher operating expenses.
us.rd.yahoo.com 2010-03-11
FDA Will Review Fosamax, Boniva for Safety
The review, of a class of drugs known as bisphosphonates that are commonly prescribed to treat osteoporosis and designed to build bone mass, will try to determine if they increase the risk of femur fractures.
online.wsj.com 2010-03-11
Heart Test May Be Overused
A widely used test to detect blockages in the heart's arteries often turns up little or no evidence of disease, a study found, suggesting that patients are frequently exposed unnecessarily to the risks and costs of the examination.
online.wsj.com 2010-03-11
Surgical-Device Firms Walk Fine Line
Heart surgery devices often used to treat a common type of faulty heartbeat haven't been approved by the government for that use. Yet these products are used almost exclusively to treat that condition.
online.wsj.com 2010-03-11
Exelixis, Inc. Q4 2009 Earnings Call Transcript
Exelixis, Inc. (EXEL)Q4 2009 Earnings CallMarch 9, 2010 8:00 am ETComplete Story »
seekingalpha.com 2010-03-10
Zygo Takeover Saga Continues
In my February 19th blog: “How to lose a lot of money in the market,” we looked at how investing in companies that are the target of unsolicited takeovers could be detrimental to the health of one’s portfolio. To illustrate this point I chose scientific equipment maker Zygo (NASDAQ: ZIGO) as my posterchild.A brief history of the proposed merger Briefly, II-VI (Nasdaq: IIVI) made an unsolicited offer for Zygo in January for $10 per share, well over the current $7 per share price. Hoping for a bidding war, investors were willing to pay up to $11 for the stock, but Zygo’s board threw cold water on that notion by rejecting the deal. The stock instantly shed a buck in value.Complete Story »
seekingalpha.com 2010-03-10
Cancer Therapeutics: The Jury's Still Out on Pixatrone
David Greene submits:With the announcement after yesterday's market close that Abbott Laboratories (NYSE:ABT) is buying Facet Biotech Corp. (NASDAQ:FACT) for approximately $450 million in cash or $27/share - a nice 67% premium to yesterday's closing market price - the focus will be on other potential targets for acquisition. Abbott said the Facet Biotech acquisition expands the company's access in immunology and oncology. The compounds include daclizumab that is expected to move into Phase III development in the second quarter 2010 to treat multiple sclerosis (MS).But there are more companies with promising drugs under development which could attract generous valuations by other Big Pharma's. Cancer Therapeutics (NASDAQ:CTIC) recently announced that the Food and Drug Administration (FDA) approved a third-party manufacturing site for the production of the company's experimental cancer drug. CTIC's drug, Pixantrone, is being reviewed by the FDA as a potential therapeutic for aggressive non-Hodgkin's lymphoma that has not responded to other approved therapies or if the lymphoma returned after initially appearing to be responding to other therapies. The FDA had expressed concerns on the efficacy and safety of Pixatrone in early February, prompting a sharp selloff in CTIC stock which is just recently rebounding from.Complete Story »
seekingalpha.com 2010-03-10
CZ Depression- Research 2010 - Video
58 procent van mensen met depressieve klachten zoekt geen professionele hulp
feedproxy.google.com 2010-03-10
China Nuokang Bio-Pharmaceutical Inc. to Report Fourth Quarter and Full Year 2009 Financial Results (GlobeNewswire)
BEIJING -- China Nuokang Bio-Pharmaceutical Inc. , a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products, today announced that it plans to release its fourth quarter and full year 2009 financial results after the market closes on Tuesday, March 16, 2010.
us.rd.yahoo.com 2010-03-10
Insight Imaging Commences Partnership Operations with American Radiology Associates (Business Wire)
LAKE FOREST, Calif.----InSight Health Services Holdings Corp. announced today that it has commenced operations in partnership with American Radiology Associates, P.A. in the Dallas metro-area.
us.rd.yahoo.com 2010-03-10
| |
ERT Launches 'Centralized Cardiac Safety 2.0': A Revolutionary New Approach to ECG Management in Clinical Trials (PR Newswire)
ERT , a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced the launch of Centralized Cardiac Safety 2.0, a portfolio of new solutions that enable a significant new approach to cardiac safety in clinical trials.
us.rd.yahoo.com 2010-03-10
Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2010 Results for March 15, 2010, at 8:30 AM E.T. (Business Wire)
NEW YORK----Enzo Biochem, Inc. , will hold a conference call to discuss its fiscal 2010 second quarter results on Monday, March 15, 2010, at 8:30 AM ET.
us.rd.yahoo.com 2010-03-10
Inverness Medical Innovations to Present at the Goldman Sachs Leveraged Finance Healthcare Conference on March 17, 2010 (PR Newswire)
Inverness Medical Innovations, Inc. , a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it will attend the Goldman Sachs Leveraged Finance Healthcare Conference being held on March 17, 2010 at the Goldman Sachs Conference Center, 32 Old Slip, New York, New York. Â Jon Russell, Vice President, Finance, will attend. Â Mr.
us.rd.yahoo.com 2010-03-10
Sanofi, Merck to Revive Venture
The drug companies said they plan to re-form a joint venture that would be the world's largest seller of animal medications, motivated in part by growing demand for livestock and meat in emerging markets.
online.wsj.com 2010-03-10
Abbott to Buy Facet Biotech
Abbott Labs will bulk up its product pipeline with a $722 million deal for Facet Biotech, which had rebuffed overtures from development partner Biogen Idec.
online.wsj.com 2010-03-10
Push to Cure Rare Diseases
FDA staff members are doing something unusual. They are leaving Washington to help drug makers take a crucial step in developing drugs for rare diseases.
online.wsj.com 2010-03-10
Five Biotech ETFs, Each Cut From a Different Cloth
Michael Johnston submits:As the array of ETF product offerings has expanded in recent years, the biotech space has seen significant activity. Currently, there are five biotech ETFs that have accumulated nearly $3.5 billion in aggregate assets. Each of these funds focuses on stocks in the biotechnology industry, and in many cases there is significant overlap between the top holdings.But as the relative performance of these funds so far this year has shown, the biotech ETFs available to U.S. investors are far from identical. Each of the biotech ETFs is up at least 6% so far in 2010, making this sector one of the best performers of the year. But the top-performing biotech ETF is up nearly 25% on the year, a significant return gap between funds that seem, at least on the surface, to be relatively comparable. Complete Story »
seekingalpha.com 2010-03-09
ISIS: Clinical Trials for Its ALS Drug
Prohost Biotech submits:Isis Pharmaceuticals (ISIS) initiated a Phase 1 study of its antisense drug ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS). As ISIS-SOD1Rx selectively inhibits the production of SOD1, it is expected to benefit the cases of familial ALS that are related to mutant forms of superoxide dismutase, or SOD1, which constitutes approximately 20% of ALS patients suffering from familial ALS. In preclinical studies, using the drug ISIS-SOD1Rx, Isis, in collaboration with Timothy Miller, Don Cleveland (University of California, San Diego), and Richard Smith (Center for Neurological Study) were able to lower the production of SOD1 in neurons and surrounding cells, which seemed to have prolonged life in rats that showed many symptoms of ALS. In December 2007, the FDA granted ISIS-SOD1Rx Orphan Drug designation for the treatment of ALS. Complete Story »
seekingalpha.com 2010-03-09
Agilent: On the Road to Recovery
Zacks.com submits: Following stellar results in the fiscal first quarter ended January 2010, Agilent Technologies’ (A) CFO, Adrian Dillon, left the company. However, despite Dillon’s long stint at Agilent, share prices did not reflect concern due to his departure. This is mainly because the company’s end markets are seeing strong recovery that Agilent is well positioned to take advantage of. Stronger MarketsComplete Story »
seekingalpha.com 2010-03-09
Merck KgaA Snaps Up Millipore in Attempt to Diversify Revenue Stream
The Burrill Report submits: Germany’s Merck KgaA (MKGAY.PK) agreed to pay $7.2 billion for lab supplier Millipore (MIL) on March 1, shutting out Thermo Fisher Scientific's (TMO) $6 billion bid for the company and surprising analysts who saw a good fit between Thermo and Millipore. Merck will pay $107 per share for Millipore, nearly a 50 percent premium to the cost of Millipore's shares before takeover speculation took hold. Both company's boards have approved the transaction, which will result in Millipore becoming a Merck subsidiary. Merck's decision to buy Millipore is indicative of the pressures facing pharmaceutical companies to diversify their revenue streams as top-selling drugs fall off-patent. For Merck, the integration of Millipore offers a shoring up of stable revenues that might help smooth the cost of surprises, like the European rejection of Erbitux for treating lung cancer last year. “By combining Millipore’s bioscience and bioprocess knowledge with our own expertise in serving pharma customers, we will be able to unlock value in our chemicals business and transform it into a strong growth driver for Merck," says Karl-Ludwig Kley, Merck's executive chairman. Merck expects that the combined business will generate annual "cost synergies" of about $100 million within three years of the transaction's close. Millipore’s headquarters in Billerica, Massachusetts will be combined with Merck’s U.S. chemicals headquarters. Just days before the March 1 sale, Millipore's board said it had retained Goldman Sachs to explore a possible merger or sale of the company but had not set a timeframe for such a transaction.Complete Story »
seekingalpha.com 2010-03-09
Cell Therapeutics: FDA Approves Italian Factory
Zacks.com submits: In a positive development, Cell Therapeutics (CTIC) announced that the US Food and Drug Administration ((FDA)) has completed its inspection of the company’s manufacturing facility in Italy and found it to be compliant with all the required norms. The facility manufactures Cell Therapeutics’ Pixuvri (pixantrone), which is currently under FDA review. Cell Therapeutics is seeking FDA approval of pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin’s Lymphoma ((NHL)) in patients who have not responded to other treatment options. A final decision on the drug should be taken by April 23. Pixantrone was supposed to be reviewed by the Oncologic Drugs Advisory Committee in a meeting scheduled for February 10, which had to be postponed due to bad weather conditions in the Washington region. A new review date of March 22 has been decided upon. Although we are pleased with the approval of the manufacturing site, we remain concerned about pixantrone’s approval due to certain issues raised by the FDA reviewers related to the study design. The study that opened in June 2004 sought to enroll 320 patients. However, the enrollment was challenging and was stopped in March 2008 after enrolling 140 patients, less than half the original plan. Overall, the reviewers are of the view that pixantrone was well-tolerated, with manageable toxicities. The pivotal study successfully met its primary efficacy endpoint. It was observed that 20% of patients receiving the drug achieved a complete remission, compared to 6% who were treated with another drug. While pixantrone could be toxic to the heart, conclusions could not be drawn about its risk compared to other cancer drugs called anthracyclines. The committee has to decide on the effectiveness of pixantrone and if risks associated with it outweigh the benefits. At present, investor focus is primarily on the outcome of the FDA advisory panel meeting, and a favorable decision should help in the final approval process. Cell Therapeutics depends heavily on the approval of pixantrone. We are also concerned about the company’s liquidity position. Operating expenses are on an uptrend as the company prepares for the potential launch of pixantrone. We have a Neutral recommendation on the stock.Complete Story »
seekingalpha.com 2010-03-09
A Cautious Look at Amgen's Denosumab
Amgen (AMGN) is global biotechnology company who sells pharmaceutical drugs, including Aranesp & Epogen (anemia), Enbrel (rheumatoid arthritis), and Neulasta & Neupogen (prevent infections in chemotherapy patients).Although there are concerns about the effectiveness and side effects of some of these drugs (notably Aranesp and Epogen), Amgen earned $4.6 billion on $14.6 billion in sales in 2009.Complete Story »
seekingalpha.com 2010-03-09
Pipeline Setback for AstraZeneca
Zacks.com submits: AstraZeneca (AZN) has received a pipeline setback with a mid-stage candidate failing to meet the primary endpoint of its study. The company was evaluating the effectiveness of Recentin (cediranib) in a phase II/III study (Horizon III) compared with Roche’s (RHHBY.PK) Avastin (bevacizumab), both in combination with chemotherapy in patients with first-line metastatic colorectal cancer (mCRC). AstraZeneca is conducting another study with Recentin (Horizon II) in first-line mCRC. The effectiveness of the drug in combination with chemotherapy is being studied against chemotherapy alone. AstraZeneca is awaiting data from this study, which is expected shortly, before taking a final decision on its regulatory filing. In addition, results from a phase III study evaluating the effectiveness of Recentin in treating recurrent glioblastoma are expected in the first half of 2010.Complete Story »
seekingalpha.com 2010-03-09
Hope for Medivation Springs Eternal
Derek Lowe submits: Well, it takes all kinds to make a market. And the collapse in Medivation's (MDVN) shares after their disastrous Phase III results the other day seems to have brought out some hopeful buyers. Take this guy: . . .I'm telling you right now, I believe that sell-off has gone twice as deep as good sense can justify. At least, that's the way I see it.Complete Story »
seekingalpha.com 2010-03-09
A GSK / Sirtris Wrap-Up
Derek Lowe submits: Nature Biotechnology weighs in on the GlaxoSmithKline (GSK)/Sirtris (SIRT) controversy. They have a lot of good information, and I'm not just saying that because someone there has clearly read over the comments that have showed up to my posts on the subject. The short form: The controversy over Sirtris drugs reached a tipping point in January with a publication by Pfizer (PFE) researchers led by Kay Ahn showing that resveratrol activates SIRT1 only when linked to a fluorophore. Although Ahn declined to be interviewed by Nature Biotechnology, a statement issued by Pfizer says the group's findings “call into question the mechanism of action of resveratrol and other reported activators of the SIRT1 enzyme.”Complete Story »
seekingalpha.com 2010-03-09
Human Genome Sciences: Novel Product Line, Significant Debt Reduction
George Chadwick submits:Much of this research on Human Genome Sciences Inc. (HGSI) was performed just prior to the company’s earnings release on March 2, 2010, in large part to help decide whether or not to continue to hold after an 80% gain (now a 90% gain) in one of our portfolios.It is interesting to note that the language used in HGSI's earnings report very closely matched what was unearthed during the research (see below). This should exemplify the usefulness of doing the research!Complete Story »
seekingalpha.com 2010-03-09
Investors Unfazed by Roche-Biogen Idec Testing Troubles
EP Vantage submits:The only surprise following news that Roche (RHHBY.PK) and Biogen Idec (BIIB) have suspended phase III trials of ocrelizumab in rheumatoid arthritis (RA) and lupus was the limited impact it had on the shares of either company. Also known as RG1594, the anti-CD20 monoclonal antibody was forecast to ring up blockbuster sales at its peak, but it now faces the prospect of being a relatively small contributor to both companies’ income in the immediate future. As ocrelizumab is a follow-on to the blockbuster Rituxan, which itself is forecast to be eclipsed by Humira this year as the best-selling RA drug worldwide if all indications are counted, one might have expected investors to react negatively to the news. However, Roche shares fell less than 0.1% yesterday and Biogen Idec shares climbed nearly 1%.Complete Story »
seekingalpha.com 2010-03-09
Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors (PR Newswire)
Genomic Health, Inc. today announced the publication of positive results from a large international study which demonstrated that the Oncotype DX® breast cancer Recurrence Score® result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive, postmenopausal breast cancer patients who are treated with either anastrozole or tamoxifen.
us.rd.yahoo.com 2010-03-09
Quest Diagnostics to offer new ovarian cancer test (AP)
Medical lab operator Quest Diagnostics Inc. said Monday it is selling the OVA1 blood test, which aims to better assess a woman's likelihood for ovarian cancer.
us.rd.yahoo.com 2010-03-09
OVA1 Blood Test Now Available to Aid Pre-surgical Evaluation of Women for Ovarian Cancer (PR Newswire)
OVA1â„¢, the first blood test cleared by the U.S. Food and Drug Administration for aiding in the pre-surgical evaluation of a woman's ovarian mass for cancer, is now available nationally through Quest Diagnostics, Inc. , the world's leading cancer diagnostics provider.
us.rd.yahoo.com 2010-03-09
Cord Blood America's New Medical Director Says Parkinson's, Diabetes Among Diseases to be Treated With Umbilical Cord Blood Stem Cells (PR Newswire)
Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company , is focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally. Â Its new Director of the Medical Advisory Board, Shamoon Ahmad, M.D., M.B.A., FACP, was interviewed about the stem cell revolution in medical care by analyst Francis Gaskins.
us.rd.yahoo.com 2010-03-09
New Risk in Pain-Reliever Use
Regular use of pain-relief medicine appears to increase men's risk of hearing loss, especially among middle-aged men, according to an American Journal of Medicine study.
online.wsj.com 2010-03-09
New Ovarian-Cancer Test
A new test will help doctors distinguish between ovarian cancer and benign growths prior to surgery, allowing patients with cancerous masses to get more effective treatment faster.
online.wsj.com 2010-03-09
|